周剂量多西他赛联合希罗达治疗晚期胃癌的疗效分析

An Analysis on Weekly Docetaxel Combined with Xeloda for 46 Cases with advanced gastric carcinoma

目的:观察周剂量多西他赛联合希罗达治疗晚期胃癌的近期疗效和毒性反应。方法:经病理学或细胞学确诊的46例晚期胃癌患者给予多西他赛与希罗达联合方案治疗:多西他赛35mg/m2,第1,8天静脉滴注1小时;希罗达1000mg/m2,口服2次/日,d1-14,21天为一周期,每例患者至少完成两个周期方可评价。结果:全组46例中,完全缓解(CR)2例(4.35%),部分缓解(PR)16例(34.8%),无变化(NC)17例(36.96%),进展(PD)11例(23.9%),总有效率(CR+PR)39.15%。初治组有效率45.45%,复治组有效率33.33%,两组差异有显著性(P<0.05)。毒副反应主要为骨髓抑制、消化道反应。结论:周剂量多西他赛联合希罗达方案治疗晚期胃癌近期疗效确切,毒性反应较轻,患者耐受性好。

Purpose:To investigate the effect and toxicity of weeklyDocetaxel combined with Xeloda for advanced gastric carcinoma.M ethods:Docetaxelcombined with Xeloda was administered to forty six cases with advanced gastric carcinoma.The patients received Docetaxel 35mg/m2, on day1 ,8 ,respectively and Xeloda PO 1000 mg/m2,twice perday on day1 to 14.The schedule was repeated every 21 days.All patients received at least 2 cycles.Results:Overall response rate was 39.15%(CR, 2 cases;PR, 16 cases;NC, 17 cases;PD, 11 cases).Theresponse rate was significant difference between the initial treated group and retreated group(45.45% vs3 3.33%,P<0.05).The main toxicitieswere myelosuppression,nausea,vomiting.Conclusion:Weekly docetaxel combined with Xeloda is effective in the treatment for advanced gastric carcinoma with mild to moderate toxicity and well tolerance.